Alf Gunnar Martin Nicklasson

Alf Gunnar Martin Nicklasson currently works at Zealand Pharma A, as Chairman, Kymab Ltd., as Non-Executive Chairman from 2017, Basilea Pharmaceutica AG, as Independent Non-Executive Director from 2016, BioCrine AB, as Director, Stockholm Chamber of Commerce, as Director, Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt, as Director, Royal Swedish Academy of Engineering Sciences, as Member, The Royal Bachelors' Club, as Member, Swedish Academy For Pharmaceutical Sciences, as Member, and Nicklasson Life Science AB, as Senior Partner from 2011.
Dr. Nicklasson also formerly worked at AstraZeneca AB, as Chief Executive Officer from 1991 to 2007, Biovitrum AB, as President & Chief Executive Officer from 2007 to 2010, Swedish Orphan International Holding AB, as Chief Executive Officer from 2007 to 2010, Astra Hässle AB, as Chief Executive Officer, Swedish Orphan Biovitrum AB, as President & Chief Executive Officer from 2007 to 2010, Astra Pain Control AB, as Chief Executive Officer, Orexo AB, as Chairman, Orexo AB, as Chairman from 2012 to 2020, Sanivo Pharma AS, as Chairman, Farma Investment AS, as Chairman, Nykode Therapeutics ASA, as Chairman from 2021 to 2025, POZEN, Inc., as Independent Director from 2011 to 2014, Premier Research Group Ltd., as Director, EffRx Pharmaceuticals SA, as Director, BioInvent International AB, as Independent Director from 2016 to 2017, BioInvent International AB, as Director, Vivesto AB, as Director from 2011 to 2012, Denator AB, as Director, Egetis Therapeutics AB, as Director, IRLAB Therapeutics AB, as Independent Director, Kymab Group Ltd., as Director from 2017 to 2021, and AstraZeneca PLC, as EVP-Product Strategy & Business Development from 1999 to 2007.
Dr. Nicklasson received his graduate degree and doctorate degree from the University of Uppsala.